Abstract. Regulatory factor X-5 (RFX5) was previously characterized as an essential and highly specific regulator of major histocompatibility class II (MHCII) gene expression in the immune system. We found that RFX5 is significantly upregulated in hepatocellular carcinoma (HCC) tumors and cell lines compared with non-tumor tissues in mRNA expression levels, but it fails to induce the expression of MHCII. However, RFX5 can strongly bind to the tripeptidyl peptidase 1 (TPP1) promoter region and then increase its transcriptional activity. We also found that manipulation the expression of RFX5 can significantly affect the expression of TPP1 in HepG2, which suggested that RFX5 can transcriptionally activate TPP1 in HCC. Moreover, TPP1 is overexpressed in HCC tissues and significantly correlated with poor prognosis of HCC patients, suggesting that it may have potential biological implications
Introduction
Regulatory factor X-5 (RFX5) belongs to the RFX family, which are winged-helix transcription factors (TFs) and characterized by a highly conserved DNA-binding domain (DBD) and dimerization motifs (1, 2) . RFX5 comprises the transcription factor complex RFX together with two other subunits, RFXANK/B and RFXAP. The most well recognized function of RFX5 and the RFX complex is to bind to MHCII gene cis-acting elements the S-Y boxes and to transactivate these genes by collaborating with NF-Y, X2BP and CIITA (3) (4) (5) (6) (7) (8) . Previous studies have found that RFX5 is not only expressed in MHCII-positive cells but also in MHCII-negative cells (3) . Moreover, our previous study found that RFX5 could be overexpressed in hepatocellular carcinoma cells that lack MHCII expression. These phenomena suggest that RFX5 may regulate the expression of non-MHCII genes, for example by transactivating MHCI and β2-microglobulin and repressing collagen gene (9, 10) . However, less effort has been made to uncover the non-MHCII transactivating target genes of RFX5 and their significance.
Tripeptidyl peptidase 1 (TPP1), which encodes a lysosomal protease and can cleave substrate N-terminal tripeptides, is known for its abolished enzyme activity that leads to lateinfantile neuronal ceroid lipofuscinosis disease (CLN2) (11, 12) . However, little is known about its role in neoplastic diseases. In our previous study, we proposed that TPP1 was a RFX5 transactivating target gene by analyzing RFX5 ChIP-seq data from the Encyclopedia of DNA Elements (ENCODE). In this
The transcription factor RFX5 is a transcriptional activator of the TPP1 gene in hepatocellular carcinoma . The media were supplemented with 10% fetal bovine serum and penicillin-streptomycin antibiotics (Gibco). The cultures were incubated in a humidified atmosphere containing 5% CO 2 at 37˚C. Cancerous and corresponding non-cancerous liver tissues were obtained from HCC patients who underwent tumor resections at the Affiliated Hospital of Guilin Medical university (Guilin, China). All patients were histopathologically diagnosed with primary HCC. The specimens were cut into small pieces and rapidly transferred to liquid nitrogen for storage. Informed consent was obtained from all the patients. This study was approved by the Ethics Committee of Peking university People's Hospital and the Affiliated Hospital of Guilin Medical university.
RNAseq and ChIP-seq data. RNAseq data, which was measured experimentally using the Illumina HiSeq 2000 RNA Sequencing platform, from liver hepatocellular carcinoma patients (LIHC) was acquired from The Cancer Genome Atlas (TCGA) project through the uCSC Cancer Genomic Browser (https://genome-cancer.ucsc.edu/, TCGA_ LIHC_exp_HiSeqV2_exon, version: 2015-02-24). The exon expression value of a gene represents the mean expression value of all exons for that gene. The raw exon expression values were normalized by independently subtracting the mean of the genomic location on the fly. Anti-RFX5 ChIP-seq data from HepG2 was acquired from the ENCODE project (http:// genome.ucsc.edu/ENCODE/terms.html) (13) .
Chromatin immunoprecipitation assay (ChIP). The ChIP assay was performed using the EZ-Zyme Chromatin Prep kit and EZ-ChIP Chromatin Immunoprecipitation kit (Millipore, Billerica, MA, uSA) according to the manufacturer's instructions. Briefly, after crosslinking with formaldehyde (Sigma-Aldrich, St. Louis, MO, uSA), HepG2 and MHCC97H cells were harvested with lysis buffer. Subsequently, chromatin was fragmented to ~200 bp pieces by enzymatic digestion. The sheared crosslinked chromatins were 'precleared' with protein G agarose, and 1% of the supernatant was preserved to be used as the Input control. The remaining DNA fragments were incubated overnight with rabbit anti-human RFX5 antibody (polyclonal, #200-401-194; Rockland, Gilbertsville, PA, uSA) or normal rabbit IgG as a negative control. Each IP product was then enriched with protein G agarose. Finally, all of the protein/DNA complexes were reverse crosslinked to free DNA fragments and purified for ChIP-PCR analysis with primers covering TPP1 promoter sequences (ChIP P1 and ChIP P2), which are listed in Table Ⅰ . PCR was performed using a 20-µl reaction volume, and 50 cycling conditions (iCycler; Bio-Rad, Hercules, CA, uSA). The PCR products were visualized with a gel documentation system (uVP, San Gabriel, CA, uSA).
Plasmids. We constructed TPP1 luciferase reporter gene vectors based on the annotated status of the TPP1 core promoter region from ENCODE histone modification profiling data and the anti-RFX5 ChIP-seq data. Briefly, the active promoter region and RFX5 binding peak in the TPP1 upstream region were included in the reporter gene. Two promoter fragments were designed that extend from nucleotides -666 to +822 bp (TPP1 P1) and -320 to +868 bp (TPP1 P2) in the TPP1 gene ( Fig. 2A) . The promoter sequences were amplified from HepG2 genomic DNA using a high-fidelity DNA polymerase (Thermo Fisher Scientific, Waltham, MA, uSA), designed with KpnI and NheI restriction sites and subsequently inserted into the pGL4.10 vector (Promega, Madison, WI, uSA); the results plasmids were named pGL4-TPP1 P1 and pGL4-TPP1 P2.
Two RFX5-specific shRNAs (RFK1, 5'-CCTCGGGAAC GGTCATCTAAA-3' and RFK2, 5'-CACTGCACCACAGGG TAATAA-3') and a non-silencing control (NS, 5'-CTGAGGT GATAAACAGTTACA-3') were cloned into the lentiviral shRNA expression vector HIV-H1 (GeneCopoeia, Rockville, MD, uSA), which contains an H1 promoter driving the shRNA expression cassette and a GFP reporter gene.
The RFX5 ORF region was amplified from HepG2 cDNA with primers (RFX5 ORF) listed in Table Ⅰ . The RFX5 ORF was fused with an N-terminal Flag Tag, subcloned into the EcoRI/XhoI sites of the retroviral vector pMSCVneo (Takara Biomedical Technology, Beijing, China) and named RFX5-pMSCV. All of the recombinant plasmids were verified by sequencing and were prepared with the Plasmid DNA Purification kit according to the manufacturer's instructions (Macherey-Nagel, Duren, Germany).
Cell transfection and luciferase assay. For exogenous overexpression of RFX5, cells were transiently transfected with RFX5-pMSCV or pMSCV-vector using the liposome reagent Turbofect (Thermo Fisher Scientific) according to the manufacturer's instructions. Gene expression efficacy was confirmed by quantitative real-time PCR and western blotting.
For luciferase assays, cells were seeded in 24-well plates and co-transfected with 0.5 µg firefly luciferase plasmid (pGL-vector, pGL4-TPP1 P1 and pGL4-TPP1 P2) and 0.5 µg RFX5 expression plasmid (pMSCV-vector or RFX5-pMSCV) together with 50 ng reference Renilla luciferase plasmid pGL4.74 (Promega). The dual luciferase activity assay was performed according to the manufacturer's instructions and detected with a liquid scintillation counter (Perkin-Elmer, Waltham, MA, uSA).
shRNA gene knockdown. Lentivirus was produced by transiently co-transfecting 293T cells with shRNA plasmid and the packing helper plasmids pLP1, pLP2 and pVSV-G (Invitrogen, Carlsbad, CA, uSA). Viral supernatants were harvested 48 or 72 h post-transfection and filtered through a 0.45-µm filter (Millipore). Viral supernatants were enriched by centrifugation in a Macrosep Advance Centrifugal Device (100K, Pall Corp., East Hills, NY, uSA). The infectious viral titer was determined using a flow cytometry assay (BD Biosciences, flow cytometry, uSA) for GFP-positive viruses in 293T cells. The viral titers were in the range of 10 9 u/ml transducing medium. HepG2 was transduced with shRNA lentivirus at an optimal multiplicity of infection (MOI, 20:1) in the presence of 4 µg/ml polybrene (Sigma-Aldrich). Transfected cells were quickly selected with puromycin for 3-5 days before use. RFX5 silencing efficacy was assessed by quantitative real-time PCR.
Western blot analysis. Total protein was extracted from cells using RIPA lysis buffer and quantified using Pierce BCA Protein Assay kit according to the manufacturer's protocol (#23225, Thermo Fisher Scientific). The protein was separated with SDS/PAGE NuPAGE Novex 4-12% gel (Thermo Fisher Scientific) and transferred to a nitrocellulose membrane. Flag-tagged RFX5 was detected with both rabbit anti-human RFX5 antibody (polyclonal, #200-401-194, Rockland) and mouse anti-human Flag-M2 antibody (monoclonal, #F3165, Sigma-Aldrich). GAPDH was detected with HRP-conjugated mouse anti-human GAPDH antibody (polyclonal, #HRP-60004, Proteintech, Chicago, IL, uSA) as a loading control.
Reverse transcriptase PCR and quantitative real-time PCR.
Total RNA was extracted with the TRIzol reagent (Invitrogen) and was reverse transcribed into cDNA (Applied Biosystems, Foster City, CA, uSA) according to the manufacturer's instructions. The quantitative real-time PCR assay was performed with a mixture containing 50 ng cDNA template and SYBR Green I Master in a LightCycler 480 (Roche Applied Science, Mannheim, Germany) for 35 cycles. Primers for RFX5, TPP1 and GAPDH are listed in Table Ⅰ . Relative gene expression was calculated with the comparative CT method and normalized against the housekeeping gene GAPDH. Each sample was tested three times.
Immunohistochemistry (IHC).
We evaluated TPP1 levels by IHC in 14 paired HCC tumors and non-tumor tissues obtained from patients diagnosed at Department of Pathology of the First Affiliated Hospital of Zhejiang university (Hangzhou Zhejiang, China) in 2015. Paraffin-embedded tissue slides were heatwd with EDTA (pH 9.0) (ZSGB-BIO, Beijing, China) for antigen retrieval and incubated with rabbit anti-human TPP1 antibody (polyclonal, #12479-1-AP, Proteintech), followed by EnVision detection system (Dako, Denmark). Sections were then counterstained with hematoxylin. The slides were observed using an Olympus AX80 digital microscopic camera system (Olympus, Tokyo, japan). This study was approved by the Ethics Committee of Peking university People's Hospital and the First Affiliated Hospital of Zhejiang university.
Statistical analysis. Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc., uSA). The unpaired t-test was used to calculate a two-tailed P-value. The Pearson correlation was used for correlation analysis. Kaplan-Meier survival analysis was used to analyze the correlation between gene expression and HCC patient prognosis. Data were considered statistically significant at P<0.05, P<0.01, P<0.001 and P<0.0001.
Results

RFX5 was upregulated in HCC but doed not induce MHCII expression.
The RNAseq data from HCC tumor tissues and adjacent non-tumor tissues from TCGA LIHC data showed that RFX5 mRNA is significantly overexpressed in HCC compared with non-tumor tissues (Fig. 1A) . The elevated RFX5 mRNA expression was further confirmed by quantitative real-time PCR analysis in an independent HCC patient cohort (Guilin cohort) (Fig. 1C, left side) . Interestingly, RFX5 overexpression does not induce MHCII expression in HCC tissues and cell lines despite the classical regulator role for RFX5 in MHCII gene transcription. Only a weak correlation was observed in the expression level of RFX5 and MHCII genes, including HLA-DRA, HLA-DMA and HLA-DQB1, which was according to the RNAseq data from the TCGA LIHC data (Fig. 1B) . The expression levels of RFX5 and HLA-DRA in the Guilin cohort detected by quantitative real-time PCR showed similar ChIP-P1  AGGATGAGGGCAAAGAGC  GAAAGGGATCACGTTGGA  ChIP-P2  GTCAACTCACGTCCTCCG  CTCCCACTGAAACCCAC  TPP1 P1  CGGCCGGGTACCTTCACTGCAATCTTTCG  CGGCCGGCTAGCTCAGAATTTGAGTTCGTAT  TPP1 P2  CGGCCGGGTACCCCCCAGTTGGAAGTAGT  CGGCCGGCTAGCCACATCCCCTTTTAGGT  RFX5 ORF CGGCCGCAATTGATGGCAGAAGATGAGCCTGATG  CGGCCGGTCGACTTATGGGGGTGTTGCTTTTGGG  RFX5  GATGAGCCTGATGCTAAGAGC  CCCTCTACTTTGTTCTGCACG  TPP1  GCCACCATCCAGTTACTTC  GTAGAGCCTTGGGTTGAGA  GAPDH CCACATCGCTCAGACACCAT GGCAACAATATCCACTTTACCAGAGT a Sequences are provided in the 5'-3' orientation. The underlined sequences are restriction endonuclease sites and protection bases.
results (Fig. 1C , right side and D). The extremely low mRNA expression of HLA-DRA in HCC cell lines by real-time PCR analysis provided more reliable evidence that high RXF5 expression levels failed to initiate the transcription of MHCII genes in HCC cells due to infiltrated immune cells, which can express both RFX5 and MHCII genes in tumor tissues, and may interfere with the results from clinical samples (Fig. 1E) . Moreover, we further manipulated the expression level of RFX5 and determined its impact on the expression of MHCII genes. Strikingly, we found that neither overexpression nor silencing of RFX5 brought any change to the expression of HLA-DRA in HepG2 (Fig. 1F) .
RFX5 directly binds to the TPP1 promoter.
The lack of MHCII expression and the overexpression of RFX5 in HCC cells suggested that RFX5 might transcriptionally regulate other genes. Thus, we analyzed RFX5 ChIP-seq data from HepG2 cells from the ENCODE project, which contains the largest collection of high-quality ChIP-seq data sets for human TFs (14) (15) (16) (17) , to genome-widely search for other possible transcriptional target genes of RFX5. We found that RFX5 can strongly bind to the promoter region (-668 to +831 bp) of TPP1, a lysosomal enzyme tripeptidyl peptidase gene in HepG2 cells ( Fig. 2A) .
ChIP-PCR was performed to validate the above finding in three HCC cell lines, HepG2 and MHCC97H. Briefly, ChIP was performed with the same RFX5 antibody used in the ENCODE project, and the immunoprecipitated DNA fragments were detected by PCR with two independent primers, which cover the RFX5 binding peak in the TPP1 promoter region that was determined by the ChIP-seq in the ENCODE database ( Fig. 2A) . The results indicated that RFX5 could bind to the TPP1 promoter region in both HCC cell lines (Fig. 2B) .
Next, we aligned the TPP1 promoter region to three of the MHCII genes and found that it contains S-X-Y motifs, which are highly-conserved in the promoter region of all of the MHCII genes (8, 18, 19) . Most importantly, the TPP1 promoter also contains an X1 box that is highly consistent with the RFX5 DNA binding motif consensus sequences predicted by the ENCODE ChIP-seq project (Fig. 2A ). These results demonstrate that RFX5 protein can directly bind to the TPP1 promoter in HCC cells and most likely bind to the X1 box in the TPP1 promoter region. 
RFX5 promotes the transcriptional activity of TPP1 promoter.
We further determined whether the binding of RFX5 to the TPP1 promoter could functionally initiate TPP1 gene transcription. Two TPP1 reporters could successfully upregulate the downstream luciferase expression to ~20-fold compared with the control group in 293T cells. The pGL4-TPP1 P1 reporter showed slightly higher transcription levels, so it was used for the following luciferase assays (Fig. 2C) . To reconfirm the regulatory effect of RFX5, a Flag-tagged RFX5 expression plasmid was constructed and validated by western blotting with both anti-Flag and anti-RFX5 antibodies (Fig. 2D) . Concurrent expression of RFX5 with the TPP1 reporter induced higher luciferase activity in both MHCC97H and HepG2 cells. The increased activation of luciferase was higher in MHCC97H cells than that in HepG2 cells, which might attribute to higher transfection efficiency (Fig. 2E) . These data suggest that RFX5 increases the transcriptional activity of the TPP1 promoter.
TPP1 expression is linked to RFX5 expression and poor prognosis in HCC.
We next determined the relationship between RFX5 and TPP1 in HCC cells and tissues. Two independent shRNAs that specifically knock down RFX5 in parallel lowered TPP1 mRNA levels compared with the control group in HepG2 cells (Fig. 3A) . Based on the RNAseq TCGA LIHC data from 421 tissues, TPP1 was significantly upregulated in HCC tumors compared with the adjacent non-tumor tissues (Fig. 3C) . Immunohistochemistry staining demonstrated that 11 of 14 cases showed TPP1 overexpression in HCC compared (Fig. 3D) . TPP1 mRNA expression increased when RFX5 was transiently overexpressed in HepG2 cells (Fig. 3B) . Moreover, RFX5 mRNA expression levels were tightly correlated with that of TPP1 in a large HCC cohort from TCGA with a R 2 of 0.52 (Fig. 3E ). Similar positive correlation was also observed in HCC samples from Guilin (Fig. 3F) . These data suggested that RFX5 could positively modulate TPP1 expression in HCC.
To assess the potential role of TPP1 in HCC patients, we carried out survival analyses in 330 HCC patients from TCGA with survival data. Patients were classified into two groups based on their TPP1 expression levels in tumor tissues. Those patients with a TPP1 expression level higher than mean value were put into the 'TPP1 high' group, while the other patients were put into the 'TPP1 low' group. Multivariate survival analysis of the data in the TCGA cohort suggested that the expression level of TPP1 is not an independent prognostic indicator for survival of HCC patients (data not shown). However, Kaplan-Meier survival analysis showed that patients with relatively lower TPP1 mRNA expression had longer overall survival times than patients with higher TPP1 mRNA expression levels (Fig. 3G ).
Discussion
Our study identified that RFX5 is overexpressed in HCC and acts as a transcriptional activator of the non-MHCII gene TPP1 in HCC. In previous studies, as a transcriptional factor encoding a DNA binding protein, RFX5 has been revealed to be a crucial MHCII gene transcription regulator. RFX5 mutations that result in severely truncated or absent proteins could lead to MHCII transcriptional deficiency (also called the bare lymphocyte syndrome, BLS), a severe immunodeficiency syndrome (3, 20) . However, our present study identified that overexpressed RFX5 in HCC tumor tissues and cell lines does not elevate MHCII expression. The heterogeneous and sparse expression of MHCII genes in HCC tumors, adjacent tissues and cell lines were also observed in previous studies and mainly attributed to mesenchymal cells in the liver sinusoid, not HCC cells (21) (22) (23) . Hence, the overexpressed RFX5 in HCC may play a role in the tumor by transactivating non-MHCII target genes, such as TPP1.
Our data showed that RFX5 could directly bind to the TPP1 promoter and most likely binds to the X1 box in the TPP1 promoter region by ChIP-seq and ChIP-PCR assay. We also proved that transient overexpression of RFX5 could increase the transcriptional levels of functionally activated TPP1 promoter by luciferase assay and modulate the expression of RFX5 in HCC cell lines, subsequently altering TPP1 expression levels. Strikingly, TPP1 mRNA and protein expression levels were elevated in HCC, and the mRNA levels were tightly correlated with that of RFX5 in two independent HCC cohorts. Most importantly, patients with higher TPP1 expression levels in HCC tissues tend to have shorter overall survival times. Although TPP1 expression may not be a good prognostic maker for HCC patients, at least in the TCGA cohort, its upregulation transactivated by RFX5 overexpression may contribute to the progress of HCC.
The above finding further supports previous studies that also identified TPP1 as a potential transcriptional target of CIITA, given that CIITA and RFX5 closely collaborate in transactivating MHCII genes (18, 24) . Moreover, RFX5 is located in 1q21, a region frequently involved in chromosomal aberrations in preneoplastic and neoplastic diseases (25) . Together, these data indicate that RFX5 itself or its downstream target genes might have more global roles in neoplastic diseases. However, the detailed molecular mechanism for RFX5 in TPP1 transcriptional regulation and its role in HCC carcinogenesis needs to be explored further.
In conclusion, this study showed that RFX5 is upregulated in HCC and transactivates the non-MHCII gene TPP1, which can lead to TPP1 overexpression and could have biological implications in HCC.
